The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies

Progress in Retinal and Eye Research

Volumn 28, Issue 2, 2009, Pages 145-154

  Schmidt Erfurth, Ursula ^a   Kiss, Christopher ^a   Sacu, Stefan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Age related macular degeneration; Antiangiogenic therapy; Hypoperfusion; Photodynamic therapy

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; STEROID; TRIAMCINOLONE; VERTEPORFIN;

CHOROID; CHOROID HYPOPERFUSION; CHOROID MELANOMA; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG UPTAKE; FLUORESCENCE ANGIOGRAPHY; FUNCTIONAL DISEASE; HUMAN; INTRAOCULAR HEMORRHAGE; NONHUMAN; PERFUSION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUBFOVEAL HEMORRHAGE; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROID; COMBINED MODALITY THERAPY; HUMANS; ISCHEMIA; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY;

EID: 59849119326     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2009.01.001     Document Type: Review

References (62)

1. Allison B.A., Pritchard P.H., and Levy J.G. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br. J. Cancer 69 (1994) 833-839
2. Arnold J.J., Blinder K.J., Bressler N.M., et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am. J. Ophthalmol. 137 (2004) 683-696
3. Attebo K., Mitchell P., and Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 103 (1996) 357-364
4. Augustin A.J., and Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmol. 113 (2006) 14-22
5. Augustin A.J., Puls S., and Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27 (2007) 133-140
6. Barber P.A., Darby D.G., Desmond P.M., et al. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology 51 (1998) 418-426
7. Blaha G.R., Wertz F.D., and Marx J.L. Profound choroidal hypoperfusion after combined photodynamic therapy and intravitreal triamcinolone acetonide. Ophthalmic Surg. Lasers Imaging 39 1 (2008) 6-11
8. Blinder K.J., Bradley S., Bressler N.M., Bressler S.B., Donati G., Hao Y., Ma C., Menchini U., Miller J., Potter J.J., Pournaras C., Reaves A., Rosenfeld P.J., Strong H.A., Stur M., Su X.Y., and Virgili G. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no.1. Am. J. Ophthalmol. 136 (2003) 407-418
9. Brown D.M., Shapiro H., and Schneider S. Subgroup analysis of first-year results of ANCHOR: a phase III, double-masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 46 (2006) 2963
10. Cardillo P.F., Eandi C.M., Ventre L., Rigault de la Longrais R.C., and Grignolo F.M. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23 (2003) 752-763
11. Costa R.A., Farah M.E., Cardillo J.A., Calucci D., and Williams G.A. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 23 (2003) 159-165
12. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J. Natl. Cancer Inst. 90 (1998) 889-905
13. European Medicines Agency (EMEA), 2007. Summary of Product Characteristics.
14. Feigl B., Brown B., Lovie-Kitchin J., and Lee L. Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases. Doc. Ophthalmol. 111 (2005) 135-148
15. Ferris III F.L., Fine S.L., and Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 102 (1984) 1640-1642
16. Fogelman A.M., Berliner J.A., Van Lenten B.J., Navab M., and Territo M. Lipoprotein receptors and endothelial cells. Semin. Thromb. Hemost 14 (1988) 206-209
17. Food and Drug Administration (FDA), 2007. Visudyne (verteporfin for injection).
18. Gaffney J., West D., Arnold F., Sattar A., and Kumar S. Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells. J. Cell Sci. 79 (1985) 317-325
19. Gelisken F., Lafaut B.A., Inhoffen W., et al. Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br. J. Ophthalmol. 88 (2004) 207-211
20. Grisanti S., Tatar O., Canbek S., et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am. J. Ophthalmol. 137 (2004) 914-923
21. Guyer D.R., Yannuzzi L.A., Slakter J.S., et al. Classification of choroidal neovascularization by digital indocyanine green videoangiography. Ophthalmology 103 (1996) 2054-2060
22. Heier, J.S., FOCUS Study Group, 2005. Intravitreal ranibizumab with verteporfin photodynamic therapy for neovascular age-related macular degeneration: year one results. Presented at the American Society of Retina Specialists 23rd Annual Meeting; July 16-20, 2005, Montreal, Canada.
23. Husain D., Miller J.W., Michaud N., Connolly E., Flotte T.J., and Gragoudas E.S. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch. Ophthalmol. 114 (1996) 978-985
24. Imaizumi M., Kitagawa K., Hashikawa K., et al. Detection of misery perfusion with split-dose 123I-iodoamphetamine single-photon emission computed tomography in patients with carotid occlusive diseases. Stroke 33 (2002) 2217-2223
25. Iriyama A., Obata R., Inoue Y., et al. Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaries hypoperfusion of photodynamic therapy. Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 339-344
26. Isola V., Pece A., and Parodi M.B. Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am. J. Ophthalmol. 142 (2006) 680-683
27. Kaiser P.K., and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension-TAP report no. 8. Graefes Arch. Clin. Exp. Ophthalmol. 244 (2006) 1132-1142
28. Kaiser P.K., and Veritas Study Group. Verteporfin therapy in combination with pegaptanib or triamcinolone for Wet AMD: 6-month results of the VERITAS trial. Invest. Ophthalmol. Vis. Sci. 48 (2007) 2870
29. Kim I.K., Husain D., Michaud N., et al. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest. Ophthalmol. Vis. Sci. 47 (2006) 357-363
30. Kiss C.G., Wagner J., Simader C., Michels S., and Schmidt-Erfurth U. Effect of photodynamic therapy (PDT) and ranibizumab on vascular anatomy and retinal function in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 48 (2007) 4544
31. Klaver C.C., Wolfs R.C., Vingerling J.R., Hofman A., and de Jong P.T. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch. Ophthalmol. 116 (1998) 653-658
32. Klein R., Wang Q., Klein B.E., Moss S.E., and Meuer S.M. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest. Ophthalmol. Vis. Sci. 36 (1995) 182-191
33. Kramer M., Miller J.W., Michaud N., et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103 (1996) 427-438
34. Liggett P.E., Colina J., Chaudhry N.A., Tom D., and Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am. J. Ophthalmol. 142 6 (2006) 1072-1074
35. Lo Giudice G., De Belvis V., Piermarocchi S., Galan A., and Prosdocimo G. Acute visual loss and chorioretinal infarction after photodynamic therapy combined with intravitreal triamcinolone. Eur. J. Ophthalmol. 18 4 (2008) 652-655
36. Michels S., Hansmann F., Geitzenauer W., and Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest. Ophthalmol. Vis. Sci. 47 (2006) 371-376
37. Michels S., and Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2147-2154
38. Miller J.W., Schmidt-Erfurth U., Sickenberg M., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch. Ophthalmol. 117 (1999) 1161-1173
39. Miller J.W., Walsh A.W., Kramer M., et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch. Ophthalmol. 113 (1995) 810-818
40. Postelmans L., Pasteels B., Coquelet P., El Ouardighi H., Verougstraete C., and Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am. J. Ophthalmol. 138 (2004) 803-808
41. Recchia F.M., Greenbaum S., Recchia C.A., et al. Self-reported acute decrease in visual acuity after photodynamic therapy for age-related macular degeneration. Retina 26 (2006) 1042-1048
42. Reinke M.H., Canakis C., Husain D., Michaud N., Flotte T.J., Gragoudas E.S., and Miller J.W. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 106 10 (1999) 1915-1923
43. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1419-1431
44. Schlotzer-Schrehardt U., Viestenz A., Naumann G.O., et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch. Clin. Exp. Ophthalmol. 240 (2002) 748-757
45. Schmidt-Erfurth U., Bauman W., Gragoudas E., et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101 (1994) 89-99
46. Schmidt-Erfurth U., and Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv. Ophthalmol. 45 (2000) 195-214
47. Schmidt-Erfurth U., Hasan T., Gragoudas E., et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101 (1994) 1953-1961
48. Schmidt-Erfurth U., Hasan T., Schomacker K., Flotte T., and Birngruber R. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg. Med. 17 (1995) 178-188
49. Schmidt-Erfurth U., Michels S., Barbazetto I., and Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest. Ophthalmol. Vis. Sci. 43 (2002) 830-841
50. Schmidt-Erfurth U., Miller J., Sickenberg M., et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch. Clin. Exp. Ophthalmol. 236 (1998) 365-374
51. Schmidt-Erfurth U., Miller J.W., Sickenberg M., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch. Ophthalmol. 117 (1999) 1177-1187
52. Schmidt-Erfurth U., Niemeyer M., Geitzenauer W., and Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 112 (2005) 2061-2069
53. Schmidt-Erfurth U., Schlotzer-Schrehard U., Cursiefen C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4473-4480
54. Schmidt-Erfurth U.M., and Pruente C. Management of neovascular age-related macular degeneration. Prog. Retin. Eye Res. 26 (2007) 437-451
55. Schmidt-Erfurth U.M., Richard G., Augustin A., et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol. Scand. 85 (2007) 486-494
56. Singh C.N., and Saperstein D.A. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 28 (2008) 789-793
57. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. 4. Retina 24 (2004) 1-12
58. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch. Ophthalmol. 119 (2001) 198-207
59. van den Bergh H., Ballini J.P., Debefve E., and Pegaz B. Video monitoring of neovessel thrombosis in real time using photodynamic therapy with verteporfin (Visudyne). Invest. Ophthalmol. Vis. Sci. 47 (2006) Abstract 914
60. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol. 131 (2001) 541-560
61. Visudyne in Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch. Ophthalmol. 123 (2005) 448-457
62. Wise R.J., Bernardi S., Frackowiak R.S., Legg N.J., and Jones T. Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain 106 Pt 1 (1983) 197-222